Platform of Polymeric Conjugates
for Selective Intracorporeal Removal
of Specific Harmful Antibodies

We are a multidisciplinary team with complementary profiles and proven experience in managing, developing, and commercializing R+D+i projects.

We truly believe that our strategy will greatly impact the patient’s health by changing the paradigm of treatment for antibody-mediated medical conditions.

Dr. Rafael Mañez
President & CMO

Dr. Daniel Bello
CSO

Montserrat Tarrés Ferrán
CCO

Pablo Madrazo
CEO

Dr. Sara Olivera Ardid
Scientific Project Manager

Yara Ferrero Alves
Specialist Technician

Dr. Anna Crespo Puig
Scientific Project Manager

Dr. Paula Ortega González
Scientific Project Manager

Scroll to Top